LOG IN

Members and suppliers: Join our online community

Access our full library of resources, register for events and webinars and share audits and other assessments

News

Sort By
This event was published on 6 November
CPHI & PMEC India

CPHI & PMEC India

External | 26–28 Nov 2024

CPHI & PMEC India unites South Asian pharma excellence. Join the event to discover innovation and connect face-to-face. Connect with thousands of industry leaders and expand your network with endless opportunities to learn, innovate, and collaborate online and in-person.

CPHI facilitates opportunities for you to grow your business and develop meaningful connections at the heart of pharma in India. Experience the latest industry trends, groundbreaking innovations, and informative sessions while networking in our match and meet lounge.

The PSCI will be exhibiting for the first time at CPHI & PMEC India as an Association Partner. Come visit us in Hall 15, Stand number 15A.C88.

Please contact the Secretariat if you are planning to attend and would like to arrange a meeting.

Type
External
Date
26–28 Nov 2024
Language
English
This bulletin was published on 30 October
The Energize Program Celebrates Landmark Multi-Buyer PPA Deal to Decarbonize Healthcare Supply Chain

The Energize Program Celebrates Landmark Multi-Buyer PPA Deal to Decarbonize Healthcare Supply Chain

Schneider Electric, the leader in the digital transformation of energy management and automation, announced exciting progress for the Energize supply chain decarbonization program, on behalf of the program’s sponsors. The first buyers’ cohort from the Energize program brings eight companies together to procure renewable energy through seven new solar projects in Spain with two developers.

Together, three sponsors of the Energize program, Takeda Pharmaceuticals International AG, Teva Pharmaceutical Industries, and UCB, along with five industry suppliers, have signed a multi-buyer PPA with developers Zelestra and Bruc adding more than 280 MW of new solar capacity to the European grid.

This multi-buyer PPA exemplifies Energize’s mission of increasing access to renewable electricity for the pharmaceutical and healthcare supply chain, while mitigating the overall environmental impact of the industry.

Five new sponsors – Almirall, Bayer, Kenvue, Sandoz, and Schott – have also joined Energize this year. The group of 24 sponsoring companies has extended their commitment to the program until 2028.

About Energize

The Energize program is a supply chain renewables initiative designed and delivered by Schneider Electric Sustainability Business and endorsed by the PSCI.

Current sponsor companies include: Almirall, Amgen, AstraZeneca, Bayer, Boehringer Ingelheim, Bristol Myers Squibb, Charles River Laboratories, Chiesi Group, GSK, Haleon, Johnson & Johnson, Kenvue, Merck (known as MSD outside the United States and Canada), Merck KGaA, Darmstadt, Germany, Novartis, Novo Nordisk, Pfizer, Roche, Sandoz, Sanofi, Schott, Takeda, Teva, and UCB.

To learn more, please contact energize@semcom.

Read the full press release here.

This resource was published on 30 October
Decarbonization Playbook for the Pharmaceutical Industry

Decarbonization Playbook for the Pharmaceutical Industry

Publication

The Pharmaceutical Supply Chain Initiative (PSCI) and Accenture are pleased to announce the publication of the Decarbonization Playbook for the Pharmaceutical Industry (Playbook), an actionable playbook to guide pharmaceutical companies and their suppliers on the road to net zero.

Climate change poses the greatest health threat of the 21st century and the pharmaceutical industry is a key contributor to global emissions due to complex product lifecycles and an energy-intensive value chain.
Many pharmaceutical companies have set ambitious, science-based decarbonization goals but only 20% of life sciences companies are on track to achieve net zero by 2050. Advancing decarbonization can be slow as companies wrestle with various pain points across the product lifecycle but delays in decarbonizing expose companies to risks across the stakeholder landscape. Decarbonizing the pharmaceutical industry is a core component of the PSCI’s Environment Principle and PSCI members realize the importance of working together and with their suppliers across the whole value chain.

There have been several whitepapers published on the topic of health sector decarbonization. This Playbook builds on that work to provide 24 detailed emissions reduction initiatives across 7 impact areas that map to the drug development lifecycle. The initiatives were assessed in terms of addressability, emission reduction potential, implementation timeline, upfront cost, and regulatory complexity, and intervention adoption timeframe.

We welcome your feedback. If you have any input on the Playbook, please contact us for consideration in future updates.

  • Decarbonization
This bulletin was published on 30 October
PSCI & Accenture Publish Decarbonization Playbook for the Pharmaceutical Industry

PSCI & Accenture Publish Decarbonization Playbook for the Pharmaceutical Industry

The Pharmaceutical Supply Chain Initiative (PSCI) and Accenture are pleased to announce the publication of the Decarbonization Playbook for the Pharmaceutical Industry (Playbook), an actionable playbook to guide pharmaceutical companies and their suppliers on the road to net zero.

Climate change poses the greatest health threat of the 21st century and the pharmaceutical industry is a key contributor to global emissions due to complex product lifecycles and an energy-intensive value chain.
Many pharmaceutical companies have set ambitious, science-based decarbonization goals but only 20% of life sciences companies are on track to achieve net zero by 2050. Advancing decarbonization can be slow as companies wrestle with various pain points across the product lifecycle but delays in decarbonizing expose companies to risks across the stakeholder landscape. Decarbonizing the pharmaceutical industry is a core component of the PSCI’s Environment Principle and PSCI members realize the importance of working together and with their suppliers across the whole value chain.

"We are thrilled to be collaborating with the PSCI, the leading nonprofit membership organization for pharmaceutical companies focused on sustainability across the global value chain. The PSCI Decarbonization Team provided critical feedback and validation to ensure the Playbook would provide pharmaceutical companies with a valuable resource for implementing decarbonization initiatives,” said Jessica Wolff, Health Sustainability Lead for Accenture.

There have been several whitepapers published on the topic of health sector decarbonization. This Playbook builds on that work to provide 24 detailed emissions reduction initiatives across 7 impact areas that map to the drug development lifecycle. The initiatives were assessed in terms of addressability, emission reduction potential, implementation timeline, upfront cost, and regulatory complexity, and intervention adoption timeframe.

The Playbook provides a double-click into each initiative looking at the value, challenges, getting started, and resources. Recognizing the complexity of the pharmaceutical industry, the Playbook also includes a section on six critical organizational capabilities necessary for successful activation of the initiatives.

"We are excited to share this action-focused resource with the industry,” said Lucy Pickett, Co-Lead of the PSCI Decarbonization Team. “The Playbook goes beyond identifying the challenges and opportunities; its deep analysis of interventions will help pharmaceutical companies in choosing how and when to implement initiatives to make real progress in their decarbonization journeys."

To download the Playbook, click here.

About PSCI
The PSCI is the leading association for pharmaceutical and healthcare companies. Through our three modes of impact – Audit, Capability and Projects – we work as one voice to deliver responsible value chains. Our vision is for excellence in safety, environmental, and social outcomes, across the global pharmaceutical and healthcare value chain. Our purpose is sector collaboration, using one voice to define, instil and drive responsible value chain practices.

About Accenture
Accenture is a global professional services company with leading capabilities in digital, cloud and security. Combining unmatched experience and specialized skills across more than 40 industries, we offer Strategy and Consulting, Technology and Operations services and Accenture Song – all powered by the world’s largest network of Advanced Technology & Intelligent Operations centers. Our 721,000 people deliver on the promise of technology and human ingenuity every day, serving clients in more than 120 countries. We embrace the power of change to create value and shared success for our clients, people, shareholders, partners and communities. Visit us at accenture.com.

  • Decarbonization
This bulletin was published on 29 October
Recap: India Supplier Conference 2024

Recap: India Supplier Conference 2024

The 2024 PSCI India Supplier Conference, held from September 24-26 in Goa, was a tremendous success, drawing over 700 participants across three days, with more than 250 attendees per day. This high turnout, thanks to the active involvement of PSCI members, reflected the strong interest in responsible supply chain practices across the sub-continent.

Keynote speeches from C-suite executives in the pharmaceutical industry set the tone for the event, delivering leadership insights. The conference also featured over 30 expert speakers who provided a range of perspectives from both the pharma sector and beyond, fostering a rich exchange of best practices. Leadership panels included representatives from top Indian pharmaceutical companies such as Glenmark and Hetero, driving critical conversations on the industry's most pressing challenges.

The event also featured the debut of the first-ever auditors' panel and exhibition, sparking insightful discussions. With 30 booths making up the exhibition, participants had valuable opportunities for networking and exchanging information.

The involvement of key institutional representatives, including the Director General of the National Safety Council and the Chairman of the Goa Pollution Control Board, underscored the importance of the event and the relevance of the topics discussed.

Many thanks are owed to the hard work and dedication of the India Sub-team who delivered the event itself, including Amish Kamat, Aditya Shirodkar, and Ranjana Ganguly, and the rest of the India team who devoted their time and efforts.

The success of this conference demonstrates the PSCI’s commitment to creating positive impact and promoting accountability, speaking as one voice for the industry.

This bulletin was published on 11 October

PSCI spreads the word of sustainability at CPHI Milan

The PSCI was proud to exhibit at CPHI Milan as one of the conference's Official Sustainability Partners for the third year in a row.

Throughout the conference, the PSCI helped demystify double materiality, engaged with manufacturers and suppliers about Supplier Partnership, and connected with our peers in the sustainability space.

  • PSCI Chair Deirdre O’Reilly joined Schott Pharma for a live experiment on Double Materiality, taking attendees through an assessment process in real time to demystify the process and reveal insights for what matters to different actors in the pharma value chain.
  • PSCI Treasurer Enric Bosch took part in the judging panel for the CPHI Award for Sustainability and handed out the award to a worthy and innovative winner.
  • At our stand, we met with companies interested in our new Supplier Partnership category and ways they can demonstrate their commitment to the PSCI Principles.

We also enjoyed connecting with fellow Sustainability and Responsible Business enthusiasts like our partners at Energize by Schneider Electric Sustainability Business, the Alliance to Zero, and the newly launched CPHI Sustainability Collective.

See you next year at CPHI Frankfurt!

This bulletin was published on 10 October
Recap: 2024 PSCI China Supplier Conference

Recap: 2024 PSCI China Supplier Conference

The 2024 PSCI China Supplier Conference, held in Nanjing on September 10-11, was a significant milestone in our efforts to promote sustainability within the pharmaceutical supply chain. With 276 attendees from 136 supplier sites across both days, the strong participation underscores the importance of responsible supply chains in our industry.

This year’s conference featured a deeper focus on critical topics such as climate change and social responsibility. Companies like Roche shared their concrete plans for decarbonising their supply chain and engaging suppliers. On the social responsibility front, AstraZeneca provided insights into helping suppliers meet PSCI's expectations for responsible labor practices, tailored to the local context in China.

The quality of discussions and presentations continues to improve year after year. This event provided valuable opportunities for learning, with attendees engaging actively in discussions and follow-up networking sessions.

We owe the success of this event to the hard work and dedication of our China sub-team, who played a key role in shaping the agenda. We also extend our gratitude to the Capability Committee and Topic teams for their efforts in ensuring that the content was both informative and impactful.

Many thanks to all members of our China team in particular the co-Leads who contributed greatly in developing the agenda and securing expert speakers; Wenjia XU, and Li Liu; and those who contributed their knowledge as speakers Gary Lu, Suijing Zhou, Wenjun Wang and Joyce Jiang.

Other companies that contributed to the event organisation and/or spoke at the event included: GSK, Novartis, Jiuzhou Pharma, DEKRA, ERM , Shanghai STRM Technology, Business for Social Responsibility, Peterson Solutions China, BSI.

As we reflect on the success of this conference, we are energized to continue our work in fostering a more sustainable pharmaceutical supply chain. We look forward to your ongoing support and participation in our future initiatives.

This bulletin was published on 25 September
PSCI Chair Deirdre O’Reilly to speak at CPHI Milan on Materiality & the Supply Chain

PSCI Chair Deirdre O’Reilly to speak at CPHI Milan on Materiality & the Supply Chain

The Pharmaceutical Supply Chain Initiative (PSCI) is delighted to be an Official Sustainability Partner for CPHI Milan, the largest international pharma industry event, for the third year in a row. We will be exhibiting throughout the conference from 8-10 October 2024 at stand 6B72 in Hall 6.0, where we will showcase the impact that the PSCI has on the pharmaceutical supply chain.

Materiality Unveiled
Materiality assessment often comes with the perception of high complexity, surrounded by uncertainty and myths. This workshop, “Materiality Assessment Unveiled,” joined by Deirdre O'Reilly, PSCI Chair and Senior Director of Global EHS Supplier Operations at Viatris, will offer a unique opportunity to collectively practice the principles of double materiality in a live, interactive experiment.

What to Expect
Participants will work in groups representing different areas of the pharma value chain, actively running a step-by-step approach from a long list of topics defined by regulation through the latest Corporate Sustainability Reporting Directive (CSRD) logics, all the way to the first assessment results.
This workshop will help answer critical questions, such as:

  1. What’s now really behind the myth of double materiality?
  2. What are the differences in methodology compared to previous approaches?
  3. What is double materiality good for?

This is an opportunity to gain hands-on experience in materiality assessments and collaborate with industry peers in a cross-industry prioritization of sustainability matters.

Event Details
Date: Wednesday, October 9, 2024
Time: 10:15 AM to 12:05 PM
Location: Hall 6 - 6A28, Sustainable Futures Theatre

For more information, visit the full conference agenda.

We look forward to seeing you at CPHI Milan 2024. If you are planning to attend and would like to book a meeting, please contact the Secretariat.

This bulletin was published on 28 August

PSCI welcomes Delpharm, Samsung Biologics, and Suven as first cohort of Supplier Partners

The Pharmaceutical Supply Chain Initiative (PSCI) has welcomed its first cohort of Supplier Partners under a new model to recognize suppliers within the pharmaceutical and healthcare industry that share its vision of building responsible supply chains.

Delpharm, Samsung Biologics, and Suven have joined the PSCI as Supplier Partners, receiving formal recognition of their commitment to the PSCI Principles, vision, and responsible business practices. These companies join a global community of pharmaceutical and healthcare companies working as one voice to drive responsible business practices.

This is a new category of partnership created as a response to the growing engagement and interest from pharmaceutical suppliers to be actively involved in PSCI activities. Supplier Partnership is open to companies in the industry that manufacture components or ingredients, manufacture finished pharmaceutical or medical products which are supplied to customers under the clients’ brand name or licence (CMOs), or a ‘white label’ service provider (such as CDOs or CROs).

Through this category, the PSCI seeks to strengthen its collaboration with suppliers, recognize those who engage, and bring their voice into relevant discussions alongside the wider membership. Supplier Partners will be able to benefit from access to the PSCI’s shared audit platform collaborate with the membership on areas of shared interest, and demonstrate their commitment to a shared vision of excellence in safety, environmental, and social outcomes across the industry.

Speaking of the new model, Dr. Deirdre O’Reilly, Chair of the PSCI & Senior Director of Global EHS Supplier Operations and Business Development at Viatris says,

I am delighted to welcome Delpharm, Samsung Biologics, and Suven as our first cohort of Supplier Partners. By solidifying the PSCI’s partnerships with suppliers, we create a stronger collaboration that promotes responsible sourcing practices across the industry. This unified approach empowers suppliers to have a voice and be recognized for their commitment to ethical sourcing and contribute to the positive impacts of the PSCI.

Nicolas Ragot, Managing Director at Delpharm says,

As a major CDMO to the pharmaceutical industry, Delpharm is proud to join the PSCI community as an official Supplier Partner. Delpharm believes that every company has a key role to play in making a difference and driving responsible value chain practices. Becoming a Supplier Partner demonstrates Delpharm’s commitment to drive excellence in safety, environmental, and social outcomes within our company and across the global pharmaceutical and healthcare supply chain.

John Rim, CEO and President of Samsung Biologics says,

The PSCI’s Supplier Partnership is a strong reaffirmation of Samsung Biologics’ commitment to achieve net zero across the supply chain. We hope to work collectively with global healthcare and pharmaceutical companies as well as suppliers to build more sustainable and responsible supply chains. We will integrate the PSCI Principles into our business practices and promote responsible conduct among our suppliers to drive sustainable change across the supply chain, contributing to creating a healthier future.

Metlapalli Srinivasu, Vice President Corp. Head of EHS & ESG at Suven Pharmaceuticals says,

Being a Supplier Partner represents a significant milestone for Suven Pharma. It accentuates our commitment to delivering high-quality pharmaceutical solutions and reinforces our role as a trusted partner in advancing global health. We are excited to contribute our expertise and collaborate closely with the PSCI to achieve our shared goals.

About the PSCI

The PSCI is the leading membership association for pharmaceutical and healthcare companies. Through our three modes of impact, Audit, Capability Building, and Projects, we work as one voice across the industry to build responsible value chains. Our 80+ members work collectively to achieve our vision for excellence in safety, environmental, and social outcomes across the global pharma and healthcare value chain.

For more information about Supplier Partnership, click here.

This event was published on 8 August
CPHI Milan

CPHI Milan

External | 8–10 Oct 2024

The PSCI is delighted to be an Official Sustainability Partner for CPHI Milan, the biggest international pharma industry event for the third year in a row.

We'll be exhibiting throughout the conference in Milan from 8-10 October 2024.

The PSCI stand 6B72 will be located in Hall 6.0, where we will be showcasing the impact that the PSCI has through the pharmaceutical supply chain.

Please contact the Secretariat if you are planning to attend and would like to arrange a meeting.

Type
External
Date
8–10 Oct 2024
Venue
Language
English
This event is in the past